NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
17856-0032-01 | 17856-0032 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 13, 2020 | In Use | ||
17478-0763-06 | 17478-0763 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 20, 2014 | In Use | |
17478-0762-06 | 17478-0762 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 20, 2014 | In Use | |
17478-0761-06 | 17478-0761 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 20, 2014 | In Use | |
17478-0547-01 | 17478-0547 | Granisetron Hydrochloride | Granisetron Hydrochloride | 0.1 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2009 | In Use | |
17478-0546-05 | 17478-0546 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2009 | In Use | |
17478-0546-04 | 17478-0546 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2009 | June 1, 2011 | In Use |
17478-0546-02 | 17478-0546 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2009 | In Use | |
17478-0546-01 | 17478-0546 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2009 | June 1, 2011 | In Use |
17478-0327-45 | 17478-0327 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 22, 2014 | In Use | ||
17478-0327-05 | 17478-0327 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 22, 2014 | In Use | ||
17156-0524-01 | 17156-0524 | Strontium Chloride Sr-89 | Metastron | 1.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Strontium Sr 89 | Intravenous | June 18, 1993 | Jan. 10, 2019 | In Use |
16729-0548-63 | 16729-0548 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Aug. 18, 2022 | In Use | |||
16729-0545-63 | 16729-0545 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Aug. 18, 2022 | In Use | |||
16729-0542-35 | 16729-0542 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Nov. 11, 2021 | In Use | |
16729-0522-64 | 16729-0522 | Pemetrexed disodium | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 8, 2022 | In Use | |
16729-0522-35 | 16729-0522 | Pemetrexed disodium | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 8, 2022 | In Use | |
16729-0522-28 | 16729-0522 | Pemetrexed disodium | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 8, 2022 | In Use | |
16729-0522-05 | 16729-0522 | Pemetrexed disodium | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 8, 2022 | In Use | |
16729-0486-01 | 16729-0486 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 24, 2020 | In Use | |
16729-0436-30 | 16729-0436 | Fulvestrant | FULVESTRANT | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Jan. 21, 2021 | In Use | ||
16729-0426-05 | 16729-0426 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 6, 2018 | In Use | |
16729-0423-33 | 16729-0423 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 24, 2018 | In Use | |
16729-0419-03 | 16729-0419 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 25, 2018 | In Use | |
16729-0391-30 | 16729-0391 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 24, 2018 | In Use |
Found 10,000 results in 13 milliseconds — Export these results